Muscle‐specific gene editing improves molecular and phenotypic defects in a mouse model of myotonic dystrophy type 1
Clinical and Translational Medicine · 2025
DOI: 10.1002/ctm2.70227 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Medicine, 2025. Verfasst von Mariapaola Izzo und 18 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biochemistry and Cell Biology, CNR, Rome, Italy. Hauptthemen laut MEDLINE: Myotonic Dystrophy, Gene Editing. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AFM-Téléthon, Fondazione Telethon, Ministero della Salute.
Abstract (Originalsprache)
Background
Myotonic dystrophy type 1 (DM1) is a genetic multisystemic disease, characterised by pleiotropic symptoms that exhibit notable variability in severity, nature and age of onset. The genetic cause of DM1 is the expansion of unstable CTG‐repeats in the 3′ untranslated region (UTR) of the DMPK gene, resulting in the accumulation of toxic CUG‐transcripts that sequester RNA‐binding proteins and form nuclear foci in DM1 affected tissues and, consequently, alter various cellular processes. Therapeutic gene editing for treatment of monogenic diseases is a powerful technology that could in principle remove definitively the disease‐causing genetic defect. The precision and efficiency of the molecular mechanisms are still under investigation in view of a possible use in clinical practice.
Methods
Here, we describe the application of the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR‐associated protein 9 (Cas9) strategy to remove the CTG‐expansion in the DMPK gene in a mouse model carrying the human transgene from a DM1 patient. To optimise the editing efficiency in vivo, we identified new tools that allowed to improve the expression levels and the activity of the CRISPR/Cas9 machinery. Newly designed guide RNA pairs were tested in DM1‐patient derived cells before in vivo application. Edited cells were analysed to assess the occurrence of off‐target and the accuracy of on‐target genomic events. Gene editing‐dependent and ‐independent mechanisms leading to decreased accumulation of the mutated DMPK transcripts were also evaluated. Results and Conclusion Systemic delivery of CRISPR/Cas9 components in DM1 mice, through myotropic adeno‐associated viral vectors, led to significant improvement of molecular alterations in the heart and skeletal muscle. Importantly, a persistent increase of body weight, improvement of muscle strength and body composition parameters were observed in treated animals. Accurate evaluation of CRISPR/Cas9‐mediated‐phenotypic recovery in vivo is a crucial preclinical step for the development of a gene therapy for DM1 patients. Key points In vivo application of a therapeutic gene editing strategy for permanent deletion of the pathogenetic CTG‐repeat amplification in the DMPK gene that causes myotonic dystrophy type 1. Following treatment, diseased mice show a significant improvement of both molecular and phenotypic defects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Biochemistry and Cell Biology, CNR, Rome, Italy.
- Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
- CNR-EMMA INFRAFRONTIER-IMPC, Rome, Italy.
- Molecular Cardiology Laboratory, IRCCS Policlinico San Donato, Milan, Italy.
- Center for Omics Sciences, IRCCS Ospedale San Raffaele, Milan, Italy.
- Sorbonne Université, Inserm, Institut de Myologie, Centre de Recherche en Myologie, Paris, France.
ORCID-Profile: Beatrice Cardinali, Fabio Martelli
Förderung
- AFM-Téléthon
- Fondazione Telethon
- Ministero della Salute
- Fondazione Monica Stupino
- European Commission
Zitieren
APA
Izzo, M., Battistini, J., Golini, E., Voellenkle, C., Provenzano, C., Orsini, T., Strimpakos, G., Scavizzi, F., Raspa, M., Baci, D., Frolova, S., Tastsoglou, S., Zaccagnini, G., Garcia-Manteiga, J. M., Gourdon, G., Mandillo, S., Cardinali, B., Martelli, F., & Falcone, G. (2025). Muscle‐specific gene editing improves molecular and phenotypic defects in a mouse model of myotonic dystrophy type 1. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.70227
Vancouver
Izzo M, Battistini J, Golini E, Voellenkle C, Provenzano C, Orsini T, et al. Muscle‐specific gene editing improves molecular and phenotypic defects in a mouse model of myotonic dystrophy type 1. Clinical and Translational Medicine. 2025. doi:10.1002/ctm2.70227
BibTeX
@article{Izzo2025,
author = {Izzo, Mariapaola and Battistini, Jonathan and Golini, Elisabetta and Voellenkle, Christine and Provenzano, Claudia and Orsini, Tiziana and Strimpakos, Georgios and Scavizzi, Ferdinando and Raspa, Marcello and Baci, Denisa and Frolova, Svetlana and Tastsoglou, Spyros and Zaccagnini, Germana and Garcia-Manteiga, Jose Manuel and Gourdon, Genevieve and Mandillo, Silvia and Cardinali, Beatrice and Martelli, Fabio and Falcone, Germana},
title = {Muscle‐specific gene editing improves molecular and phenotypic defects in a mouse model of myotonic dystrophy type 1},
journal = {Clinical and Translational Medicine},
year = {2025},
doi = {10.1002/ctm2.70227}
}
EUVIMED